ro13-9904 and Cognitive-Dysfunction

ro13-9904 has been researched along with Cognitive-Dysfunction* in 2 studies

Reviews

1 review(s) available for ro13-9904 and Cognitive-Dysfunction

ArticleYear
Secondary dementia due to Lyme neuroborreliosis.
    Wiener klinische Wochenschrift, 2018, Volume: 130, Issue:15-16

    Dementia-like syndromes are rare manifestations of Lyme neuroborreliosis. The clinical patterns are summarized using our own cases and case reports from the literature, which were diagnosed as definite Lyme neuroborreliosis according to the European guidelines. The cases disclose signs of subcortical dementia that occur more rapidly than in patients suffering from primary dementia. Gait disturbances early in the disease course is another frequently observed characteristic feature. The response to 2-4 weeks of antibiotic treatment with ceftriaxone was excellent. There were no indications for a prolonged antibiotic treatment. It is essential to be aware of this manifestation of Lyme neuroborreliosis, because early antibiotic treatment will prevent permanent sequelae that may occur throughout the further course of the untreated disease.

    Topics: Aged, 80 and over; Anti-Bacterial Agents; Ceftriaxone; Cognitive Dysfunction; Dementia; Female; Humans; Lyme Disease; Lyme Neuroborreliosis

2018

Other Studies

1 other study(ies) available for ro13-9904 and Cognitive-Dysfunction

ArticleYear
Pharmacological upregulation of GLT-1 alleviates the cognitive impairments in the animal model of temporal lobe epilepsy.
    PloS one, 2021, Volume: 16, Issue:1

    It is known that hippocampal epileptogenesis is accompanied by hyperexcitability, glutamate-related neuronal dysfunctions and consequently cognitive deficits. However, the neuroprotective role of astrocytic glutamate uptake through the Glutamate Transporter-1 (GLT-1) remains to be unknown in these processes. Therefore, to assess the effect of glutamate uptake, pharmacological upregulation of GLT-1 using ceftriaxone administration (200 mg/kg/day, i.p, 5 days) was utilized in Li-PIL animal models of temporal lobe epilepsy (TLE). Glutamate concentration and glutamine synthetase activity were analyzed using biochemical assays. In addition, GLT-1 gene expression was assessed by RT-qPCR. Finally, cognitive function was studied using Morris water maze (MWM) test and novel object recognition task (NORT). Our results demonstrated that the acute phase of epileptogenesis (first 72 hours after Status Epilepticus) was accompanied by an increase in the hippocampal glutamate and downregulation of GLT-1 mRNA expression compared to controls. Ceftriaxone administration in epileptic animals led to a reduction of glutamate along with elevation of the level of glutamine synthetase activity and GLT-1 expression in the acute phase. In the chronic phase of epileptogenesis (4 weeks after Status Epilepticus), glutamate levels and GLT-1 expression were decreased compared to controls. Ceftriaxone treatment increased the levels of GLT-1 expression. Furthermore, impaired learning and memory ability in the chronic phase of epileptogenesis was rescued by Ceftriaxone administration. This study shows that astrocytic glutamate uptake can profoundly impact the processes of hippocampal epileptogenesis through the reduction of glutamate-induced excitotoxicity and consequently rescuing of cognitive deficits caused by epilepsy.

    Topics: Animals; Ceftriaxone; Cognitive Dysfunction; Disease Models, Animal; Epilepsy, Temporal Lobe; Excitatory Amino Acid Transporter 2; Male; Maze Learning; Neuroprotective Agents; Rats; Rats, Wistar; Recognition, Psychology; Treatment Outcome; Up-Regulation

2021